Overview

Study Evaluating ReFacto in Hemophilia A

Status:
Completed

Trial end date:
2001-05-01

Target enrollment:

Participant gender:

Summary

To identify the causative mutations in previously untreated patients with hemophilia A enrolled in the ReFacto® clinical safety and efficacy study CTN 93-R833-0XX/C9741-28, using two established hemophilia mutation testing laboratories (one in Europe and one in North America).

Phase:

N/A

Details

Lead Sponsor:

Wyeth is now a wholly owned subsidiary of Pfizer

Treatments:

Factor VIII